Ark Therapeutics reveals VEGF D trials progressing well

Ark Therapeutics has revealed that the trials involving its VEGF D refractory angina treatment appear to be promising and are progressing well.

VEGF D – an adenoviral short-form Vascular Endothelial Growth Factor D gene construct (Ad-VEGF D) – is undergoing clinical development for the treatment of the condition in collaboration with the AI Virtanen Institute in Kuopio, Finland.

Manufacturing in accordance with official guidelines has already been completed at the institute, Ark has revealed.

“The shortform VEGF D gene has shown increasing promise as an angiogenic treatment agent and we have already identified patients who would be suitable for this new medical approach,” stated Professor Yla-Herttuala, consultant director of molecular medicine at the company.

This news comes after Ark launched the Kerraglove in the UK in July – a dressing device in the shape of a mitten that is designed to manage exudate in hand injuries, specifically burns.